Actin, the most common protein in eukaryotic cells, is involved in numerous vital cellular functions including cell shape maintenance, division, locomotion, and adhesion.^[@ref1]^ Actin dynamics are normally tightly controlled by a number of actin-binding proteins; dysregulation has been implicated in diseases including stroke, cystic fibrosis, and cancer.^[@cit1a],[@ref2]^

Aplyronines A--H^[@ref3]^ (Figure [1](#fig1){ref-type="fig"}) comprise a family of actin-binding marine macrolides that can serve as small molecule mimics of actin-binding proteins. They were isolated in low yield (10^--5^--10^--7^% based on wet weight) from the Japanese sea hare *Aplysia kurodai* by Yamada and co-workers based on their potent cytotoxicity against HeLa-S3 cells.^[@ref4]^ Notably, the antiproliferative efficacy of aplyronine A (**1**) has been demonstrated *in vivo* against P388 leukemia (T/C 545%, 0.08 mg/kg) and Lewis lung carcinoma (T/C 556%, 0.04 mg/kg), leading to its identification as a promising anticancer drug candidate.^[@ref5]^ Aplyronine A forms a 1:1 complex with globular actin (G-actin, *K*~d~ = 100 nM), inhibiting polymerization, and also depolymerizes fibrous actin (F-actin).^[@ref6]^ X-ray analysis of the actin--aplyronine A crystal structure,^[@ref7]^ structure--activity relationship studies,^[@ref8]^ and photoaffinity studies^[@ref9]^ have highlighted the importance of the C24--C34 tail region in the strong actin depolymerizing activity. The mechanism of cytotoxicity for these macrolides remains unelucidated. Recent work has shown that aplyronine A causes caspase-dependent apoptosis with rapid disassembly of the actin cytoskeleton and dephosphorylation of focal adhesion kinase^[@ref10]^ and has suggested an interaction between the aplyronine--actin complex and a secondary biomolecule such as Arp2/3.^[@ref11]^
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The aplyronines have elicited significant interest for their potent antitumor activities and novel actin-binding properties, as well as their unique structures.^[@ref11]−[@ref16]^ Moreover, they hold great potential for the development of biomolecular probes and novel actin-targeting therapeutic agents. It is a testament to the severe challenge presented by these complex polyketides that, despite considerable effort from several groups,^[@ref12]−[@ref16]^ only one prior total synthesis of aplyronines A--C has been achieved, as reported by Yamada and Kigoshi.^[@cit16a]−[@cit16c]^

In our previous work toward the aplyronines (Scheme [1](#sch1){ref-type="scheme"}), we reported the synthesis of an advanced macrocyclic intermediate **4**([@cit12a],[@cit12b]) and β-ketophosphonate **5**([@cit12c]) in pursuit of an aborted HWE fragment coupling strategy. Here, we describe the synthesis of a more suitable aldol coupling partner **6**, enabling completion of the total synthesis of aplyronine C (**2**) and providing access to some novel C21--C34 tail analogs.

Our revised strategy hinges on a key aldol fragment coupling between the C1--C27 aldehyde **7**, derived from previously synthesized macrocycle **4**, with the (*E*)-*N*- methyl-*N*-vinylformamide-bearing methyl ketone **6**. The strategic decision to incorporate the terminal (*E*)-vinylformamide into the coupling fragment was influenced by our recent total syntheses of reidispongiolide A^[@ref17]^ and rhizopodin,^[@ref18]^ and contrasts with more established approaches in which this sensitive moiety is introduced by a testing, late-stage condensation reaction with a highly functionalized C34 aldehyde.
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The synthesis of the C28--C34 methyl ketone **6** is outlined in Scheme [2](#sch2){ref-type="scheme"}. It commenced with a Sn(II)-mediated aldol reacton^[@ref19]^ between known (*R*)-Roche ester-derived ketone **8**([@cit12a]) and acetaldehyde to generate the all *syn* aldol adduct **9** with high yield and selectivity (97%, 15:1 *dr*).^[@ref20]^ A directed 1,3-*anti* reduction under Evans--Tishchenko conditions^[@ref21]^ set the C31 stereocenter and concomitantly capped the C29 alcohol as the ester (**10**).^[@ref22]^ Following silyl protection, the C29 and C33 alcohols were revealed to produce diol **11**.

Oxidation of diol **11** to the corresponding keto-aldehyde required that the primary and secondary alcohols be oxidized concurrently, lest intramolecular cyclization onto the nascent aldehyde form an undesired hemiacetal. This was achieved using a double Swern oxidation.^[@ref23]^ Following our Wittig protocol for the synthesis of *N*-methyl-*N*-vinylformamides,^[@ref24]^ the ylide of phosphonium salt **12** (LiHMDS) reacted selectively with the aldehyde to introduce the *N*-vinylformamide terminus in **13**, predominantly in the (*Z*)-configuration (75% over two steps, 8:1 *Z*/*E*). Two further steps introduced the C31 acetate moiety; isomerization to (*E*)-vinylformamide **6** then proceeded smoothly in the presence of stoichiometric iodine under light-free conditions.^[@ref24]^ While all β-acetoxy ketone intermediates were prone to elimination and required careful handling, introduction of the C31 acetate moiety at this early stage proved crucial. Attempted isomerization of fragments bearing a C31-OTES (**13**) or -OPMB group failed to provide the desired (*E*)-vinylformamide under a variety of conditions. The C28--C34 fragment **6** was thus accessed by an efficient 10 step sequence in 60% overall yield.
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Aldehyde **7** was readily accessible in four steps from our previously reported macrocyclic intermediate **4** (Scheme [3](#sch3){ref-type="scheme"}). Accordingly, global deprotection with aqueous HF was followed by TES protection of the resultant tetraol. Selective unveiling of the C27 primary alcohol under mild conditions (THF/H~2~O/AcOH) and subsequent oxidation provided the desired aldehyde **7**.

With C1--C27 aldehyde **7** and C28--C34 ketone **6** in hand, attention turned to assembly of the full aplyronine backbone.^[@ref25]^ Owing to the complexity of the aldehyde **7** and the acid and base sensitivity of methyl ketone **6**, especially mild conditions were required. Initially, we rehearsed this crucial fragment coupling and endgame using **14** as a truncated model for aldehyde **7**.^[@ref26]^ Boron-mediated aldol coupling conditions proved uniquely effective, leading to two novel C21--C34 tail analogs for the aplyronines (**15** and **16**; Scheme [4](#sch4){ref-type="scheme"}).^[@ref27]^
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Application of the boron aldol coupling conditions to real aldehyde **7** successfully formed the desired C27--C28 bond (Scheme [5](#sch5){ref-type="scheme"}).^[@ref17]^ After careful optimization, we were able to perform this delicate aldol coupling using *c*-Hex~2~BCl/Et~3~N for enolization of **6** at −10 °C followed by slow addition of the enolate (3 equiv) to aldehyde **7** at −78 °C. Following a mild, nonoxidative workup, β-hydroxy ketone **17** was obtained in 61% yield with good recovery of the excess ketone **6**.
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Deoxygenation at C27 was achieved using a two-step procedure:^[@ref17]^ the β-hydroxy ketone **17** was dehydrated with the Burgess reagent (Et~3~NSO~2~NCO~2~Me)^[@ref28]^ to the corresponding enone, which was subsequently reduced in a 1,4-sense to ketone **18** using Stryker's reagent.^[@ref29]^ Under these conditions, elimination of the potentially labile β-acetoxy ketone was minimized, and complete selectivity for reduction of the enone over the sensitive α,β,γ,δ-unsaturated dienoate was obtained.

From this point, all that remained to obtain aplyronine C (**2**) was stereoselective reduction of the C29 ketone, installation of the appropriate C29 amino ester, and global deprotection. Screening reduction conditions on the model system^[@ref26]^ revealed that ketone **19** exhibits moderate inherent diastereoselectivity for the desired C29 epimer (NaBH~4~, 2:1 *dr*; entry 1, Table [1](#tbl1){ref-type="other"}). Attempts to enhance this selectivity using bulky reducing agents (entries 2--3) led primarily to formation of elimination-related byproducts. Luche conditions^[@ref30]^ (entry 4) appeared more promising, giving an improved 7:1 *dr* but a disappointingly low yield. Ultimately, Zn(BH~4~)~2~^[@ref31]^ was found to provide the desired alcohol **20** in 10:1 *dr* and 77% yield (entry 5).

Pleasingly, this result transferred well to the real system **18** (Scheme [6](#sch6){ref-type="scheme"}). The desired diastereomer at C29 (**21**) was obtained with good selectivity by reduction with Zn(BH~4~)~2~ (90%, 10:1 *dr*). Esterification with (*S*)*-N*,*N-*dimethylalanine under Keck conditions^[@ref32]^ (DCC, DMAP, CSA), as precedented by Yamada,^[@cit16a]^ was followed by global deprotection using HF•py and pyridine to provide (+)-aplyronine C (**2**). To our satisfaction all ^1^H and ^13^C NMR spectroscopic data for this synthetic material correlated with those reported for natural aplyronine C.^[@cit3a]^

###### Model Studies of C29 Reduction
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  entry   conditions                                 yield (%)                            *dr*
  ------- ------------------------------------------ ------------------------------------ ------
  1       NaBH~4~, MeOH, rt                          55                                   2:1
  2       [l]{.smallcaps}-selectride, THF, --78 °C   --[a](#t1fn1){ref-type="table-fn"}   --
  3       LiAlH(O*t*-Bu)~3~, THF, −10 °C → rt        --[a](#t1fn1){ref-type="table-fn"}   --
  4       NaBH~4~, CeCl~3~·7H~2~O, MeOH, 0 °C        34                                   7:1
  5       Zn(BH~4~)~2~, Et~2~O, 0 °C                 77                                   10:1

Slow reaction rate, forming predominantly elimination and decomposition products.

In conclusion, this highly stereocontrolled total synthesis of aplyronine C was completed in 28 steps (LLS) and 3.6% overall yield, by a route that is significantly shorter than the previous synthesis (45 steps LLS).^[@cit16b]^ Alcohol **21** represents an advanced common intermediate from which we can access other members of the aplyronine family. Studies toward these congeners and other novel analogs will be reported in due course.
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